The associations between the presence or severity of coronary artery disease (CAD) and measurements of various kinds of fat as assessed by multidetector row computed tomography (MDCT) are unclear. We enrolled 300 patients who were clinically suspected to have CAD or who had at least one cardiac risk factor and had undergone MDCT. The number of significantly stenosed coronary vessels (VD), and measurements of pericardial fat index, paracardial fat index, epicardial fat index, visceral fat index, and subcutaneous fat index were quantified using MDCT. Plasma levels of adiponectin, pentaxin-3, and high-sensitivity C-reactive protein factors were also measured. Pericardial fat index, paracardial fat index, and visceral fat index in a CAD group were significantly greater than those in a non-CAD group. In addition, the levels of these fat indices tended to increase as the number of VD increased and were positively correlated with the Gensini score. The area-underthe-curve for paracardial fat index was significantly greater than those for the other parameters of fat index measured by a receiver-operating characteristic curve analysis. The cut-off level of paracardial fat index that gave the greatest sensitivity and specificity for the diagnosis of CAD was 54.9 cm 3 /m 2 (sensitivity 0.710, specificity 0.552). The presence of CAD was independently associated with paracardial fat index, in addition to age and diabetes mellitus, by a multiple logistic regression analysis. In conclusion, paracardial fat index may be a marker for evaluating the presence or severity of CAD.
C oronary artery disease (CAD) is mainly caused by arteriosclerosis. There are various risk factors for CAD, such as hypertension (HTN), diabetes mellitus (DM), dyslipidemia (DL), and metabolic syndrome (MetS). In Japan, MetS is diagnosed according to the modified guidelines as visceral fat area !100 cm 2 and the presence of two or more of the following: high blood pressure (BP) [systolic BP (SBP) !130 mmHg or diastolic BP (DBP) ! 85 mmHg or taking an antihypertensive drug], DL [triglycerides (TG) !150 mg/dL or 40 mg/dL > high-density lipoprotein cholesterol (HDL-C) or high fasting glucose (fasting glucose !110 mg/dL or taking a glucose-lowering drug). 1) Many studies have shown that visceral fat has a detrimental effect on metabolism and the risk of CAD. [2] [3] [4] The best tool for estimating visceral fat is multi-detector row computed tomography (MDCT). MDCT has become more widely available in many general hospitals, and enables the accurate noninvasive assessment of coronary artery stenosis, 5) calcification, 6) and plaque imaging.
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Recently, ectopic fat has attracted attention. Surplus ectopic fat accumulates in several organs, such as the heart, liver and muscle, which contain just a small amount of adipose tissue. The fat located around the heart is called pericardial fat. Pericardial fat consists of paracardial fat and epicardial fat. Paracardial fat is located on the epicardium surface and epicardial fat is located between the epicardium and myocardium, and each type of cardial fat can be scanned by MDCT. Several studies have supported the notion that ectopic fat is associated with MetS and insulin resistance, 8) and a positive correlation has been Ueda, ET AL shown to exist between pericardial fat and visceral fat. 9) However, the association between the presence or severity of CAD and pericardial fat is unclear, and it is not known which types of fats are most closely associated with the presence or severity of CAD. Therefore, we determined, among the levels of pericardial fat, paracardial fat, epicardial fat, visceral fat, and subcutaneous fat, which is most closely associated with the presence and severity of CAD.
Methods
Study Subjects: Three hundred consecutive subjects who were clinically suspected of having CAD or who had at least one cardiac risk factor were enrolled in this study. All subjects underwent MDCT coronary angiography between April 2012 and July 2014. Patients with serum creatinine > 2.0 mg/dL or contrast-induced allergy did not undergo MDCT. The protocol in this study was approved by the ethics committee of Fukuoka University Hospital [IRB #11-06(09-089)], and all subjects gave their informed consent to participate. Evaluation of coronary stenosis using MDCT: We evaluated coronary stenosis using MDCT as previously described. 10) Of the 300 patients, 208 who underwent MDCT were scanned by 64-MDCT on an Aquilion 64 (Toshiba, Tokyo), and 92 patients who underwent MDCT were scanned by 320-MDCT on an Aquilion ONE Vi-SION (Toshiba, Tokyo). The use of a beta-blocker and nitroglycerin before scanning was left to the physician's discretion. In the first MDCT, a 70 mL bolus of contrast medium (Omnipaque, 350 mg iodine/mL; Daiichi Sankyo Co., Ltd., Tokyo) was injected at a flow rate of 3.6 mL/ sec, followed by 35 mL contrast agent and 30 mL saline solution, each at a flow rate of 1.8 mL/sec, with a dual injector. In the second MDCT, 21.5 mgI/kg/second contrast medium (Iopamiron, 370 mg iodine/mL; Bayer Yakuhin Ltd, Osaka, Japan) equivalent to the patient's body weight × 0.7 mL was injected over 10 seconds, followed by 35 mL contrast agent and 30 mL saline solution, each at a flow rate of 1.8 mL/second, with a dual injector.
The region of interest was placed within the ascending aorta, and the scan was started when the CT density reached 100 Hounsfield units higher than the baseline CT density. The scan was performed between the tracheal bifurcation and diaphragm with the following parameters: 64-MDCT-collimation width 0.5 mm, rotation speed 0.4 seconds/rotation, tube voltage 135 kV, and effective tube current 360 mA; 320-MDCT-collimation width 0.5 mm, rotation speed 0.275 seconds/rotation, tube voltage 120 kV, and auto tube current.
Overall, 15 coronary artery segments were assessed in all patients. Narrowing of the normal contrast-enhanced lumen to !50% that could be identified in multiplanar reconstructions or cross-sectional images was defined as significant stenosis in CAD. In addition, in all patients, the atherosclerotic severity of coronary artery disease was assessed in terms of the Gensini score. 11, 12) Measurement of pericardial fat, paracardial fat, epicardial fat, visceral fat, and subcutaneous fat: CT scans were performed with a MDCT and a workstation on a Ziostation (Ziosoft Inc., Tokyo). Pericardial fat was defined as pixels within a window level of -195 to -45, and the volume of fat was measured from the bifurcation of the pulmonary artery to the diaphragm. 3, 13) The pericardium was traced manually. Intrapericardial fat was defined as epicardial fat, and fat outside the pericardium was defined as paracardial fat. Figure 1 shows representative images obtained using 64-MDCT and 320-MDCT. In addition, to measure the areas of visceral fat and subcutaneous fat, as well as waist circumference (WC), a CT scan was also performed. These values were measured from CT cross-sectional scans at the level of the umbilicus with a workstation on a Ziostation (Ziosoft Inc.). Each fat index was obtained by dividing the value for each type of fat by the body surface area. Evaluation of risk factors for CAD: Body mass index (BMI), SBP, DBP, serum levels of total cholesterol (TC), TG, HDL-C, low-density lipoprotein cholesterol (LDL-C), ratio of LDL-C to HDL-C (L/H-C), non HDL-C (TC minus HDL-C), uric acid (UA), fasting glucose, hemoglobin A1c (HbA1c), high-sensitivity C-reactive protein (hsCRP), adiponectin, pentraxin 3 (PTX-3), smoking status (current versus nonsmokers), family history [myocardial infarction (MI), angina pectoris or sudden death] and medication use were collected as risk factors in all patients. Plasma levels of adiponectin and PTX-3 were determined in duplicate by specific enzyme immunoassays (R&D Systems, Minneapolis, MN) according to the manufacturer's protocol.
BMI was calculated as weight (kg)/height (m) 2 . BP was determined as the mean of two measurements obtained in an office setting by the conventional cuff method using a mercury sphygmomanometer after at least 5 minutes of rest. All of the blood samples were drawn in the morning after the patient had fasted overnight. The patient characteristics were obtained from medical records with regard to history of HTN, DL, DM, and history of smoking. Patients who had a current SBP/DBP ! 140/90 mmHg or who were receiving antihypertensive therapy were considered to have HTN. Patients with LDL-C !140 mg/dL, TG !150 mg/dL, and/or HDL-C < 40 mg/dL or who were receiving lipid-lowering therapy were considered to have DL. 14) DM was defined using the American Diabetes Association criteria 15) or the administration of a glucose-lowering drug. Hyperuricemia (HU) was defined as a serum uric acid level of !7.0 mg/dL or the administration of uric acid-lowering drugs. Statistical analysis: A statistical analysis was performed using Excel 2016 (SSRI, Tokyo), the Stat View statistical software package (Stat View 5; SAS Institute Inc, Cary, NC, USA) and EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan). Continuous variables are shown as the mean ± standard deviation. Categorical and continuous variables were compared between the groups by a chi-square analysis and t-test, respectively. A receiver-operating characteristic (ROC) curve analysis was used to determine the cut-off levels of pericardial fat index, paracardial fat index, epicardial fat index, visceral fat index, and subcutaneous fat index to distinguish between the presence and absence of CAD at the highest possible sensitivity and specificity levels. Multivariate analysis was performed by a logistic regression analysis for independ-CORONARY ARTERY DISEASE AND PARACARDIAL FAT ent variables that were related to the presence or absence of CAD. A value of P < 0.05 was considered significant. Table I shows the characteristics of the 300 patients (150 (50%) men and 150 (50%) women). There were significant differences in patient characteristics between the CAD and non-CAD groups. The CAD group showed a significantly higher age, % HT, SBP, % DM, fasting glucose, HbA1c, % DL, TG, L/H-C, visceral fat index, % MetS, hsCRP, pericardial fat index, paracardial fat index, and epicardial fat index, and significantly lower % females and HDL-C levels than the non-CAD group. Table II shows the medications in all patients and in the CAD and non-CAD groups. The percentages of the use of an angiotensin II receptor blocker (ARB)/ angiotensin-converting enzyme inhibitor (ACEI), calcium channel blocker (CCB) and statin in all patients were 42%, 37% and 32%, respectively. There were significant differences in medications between the CAD and non-CAD groups. The CAD group showed significantly higher use of ARB/ACEI, CCB, statin, β-blocker, sulfonylurea (SU), α-glucosidase inhibitor (α-GI) and dipeptidyl peptidase-4 inhibitor (DPP-4I) than the non-CAD group. Measurements of pericardial fat index, paracardial fat index, epicardial fat index, visceral fat index, subcutaneous fat index in the CAD and non-CAD groups: As shown in Figure 2 , we analyzed whether there were differences in the pericardial fat index, paracardial fat index, epicardial fat index, visceral fat index and subcutaneous fat index between the CAD and non-CAD groups. The pericardial fat (P = 0.0008), paracardial fat (P < 0.0001) and visceral fat indices (P = 0.008) in the CAD group were significantly higher than those in the non-CAD group. Association between pericardial fat index, paracardial fat index, epicardial fat index, visceral fat index, or subcutaneous fat index and the number of significantly stenosed coronary vessels (VD): The subjects were divided into 4 groups (0, 1, 2 and 3VD groups) according Ueda, ET AL Continuous variables are expressed as mean ± SD. CAD indicates coronary artery disease; BMI, body mass index; HTN, hypertension; SBP, systolic blood pressure; DBP, diastolic blood pressure; DM, diabetes mellitus; DL, dyslipidemia; TG, triglyceride; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; L/H-C, a ratio of LDL-C to HDL-C; Non HDL-C, total cholesterol minus HDL-C; HU, hyperuricemia; MetS, metabolic syndrome; WC, waist circumference; VFA, visceral fat area; SFA, subcutaneous fat area; HsCRP, high-sensitivity CRP; and PTX-3, pentraxin-3.
Results
Patient characteristics in all patients and the CAD and non-CAD groups:
to the number of significantly stenosed coronary vessels ( Figure 3 ). Pericardial fat index, paracardial fat index, epicardial fat index, and visceral fat index, but not subcutaneous fat index, increased slightly as the number of VD increased. Subjects with multi-VD (2 and 3 VD) had significantly higher paracardial fat and visceral fat indices than those with 0 VD (data not shown). highest AUC, although there was a small difference in AUC among the 5 types of fat index. The cut-off level of paracardial fat index that gave the greatest sensitivity and specificity for the diagnosis of CAD was 54.9 cm 3 /m 2 . Predictors of the presence of CAD, including paracardial fat index: We analyzed the predictors of the presence of CAD in all patients using independent variables by logistic regression analysis (Table III) . We selected conventional coronary risk factors (gender, age, BMI, HTN, DL, DM and smoking) and paracardial fat index as variables. The presence of CAD was independently associated with paracardial fat index (P = 0.015), in addition to age (P < 0.001), gender (P = 0.019), and DM (P = 0.010). We also analyzed the predictors of the presence of CAD in all patients using independent variables including conventional coronary risk factors and pericardial fat index (Supplemental Table I ), epicardial fat index (Supplemental Table  II ), or visceral fat index (Supplemental Table III ) by logistic regression analysis. Finally, the presence of CAD was not associated with pericardial fat (P = 0.115), epicardial fat (P = 0.632), or visceral fat (P = 0.669).
Discussion
In the present study, we investigated the association between pericardial fat index, paracardial fat index, epicardial fat index, visceral fat index, or subcutaneous fat index and the presence or severity of CAD as assessed by MDCT. Pericardial fat index, paracardial fat index, epicardial fat index, and visceral fat index, but not subcutaneous fat index, were associated with the presence or severity of CAD. In particular, the presence of CAD was independently associated with paracardial fat index in addition to age, gender and DM by a multiple logistic regression analysis.
Several studies have shown that epicardial fat was associated with CAD risk and coronary atherosclerosis.
3) [16] [17] [18] Although Rosito, et al. 3) analyzed the association between epicardial fat or paracardial fat and vascular calcification, they did not consider the presence of significant coronary stenosis. Three other studies did not analyze various kinds of fat including paracardial fat and visceral fat. [16] [17] [18] Rodriguez-Granillo, et al. reported that pericardial fat volume was associated with the atherosclerotic plaque burden rather than the severity of lesions in coronary arteries. 19) They did not analyze epicardial fat or paracardial fat. In addition, Ghaderi, et al. reported that epicardial fat thick-Ueda, ET AL ness measured by echocardiography can be used as an independent marker to predict CAD. 20) They did not measure paracardial fat. Importantly, they analyzed the thickness, but not the volume, of pericardial fat. Furthermore, while they used echocardiography to measure fat values, we used CT. On the other hand, we analyzed 5 fat values (epicardial fat, pericardial fat, and paracardial fat in addition to visceral fat and subcutaneous fat) using CT. These other studies did not measure visceral fat or subcutaneous fat. Thus, there are many differences between our study and previous studies with regard to the methods used and the kinds of fat examined. Finally, we determined which of 5 kinds of fat was the most useful for predicting the presence of CAD. Thus, our report is the first to analyze the associations between 5 kinds of fat indexes and the presence or severity of coronary artery disease.
Epicardial fat is located between the epicardium and myocardium. Epicardial fat originates in the splanchnopleuric mesoderm and vascularization for epicardial fat is supplied by a branch of the coronary artery. 21) On the other hand, paracardial fat is located at the epicardium surface and originates in the primitive thoracic mesenchyme. 21) Vascularization for paracardial fat is supplied by non-coronary sources. In addition, visceral fat accumulates around abdominal viscera and inside intraabdominal solid organs. A previous study demonstrated an association between atherosclerosis and visceral fat, but not subcutaneous fat. 22) Visceral adipose tissue and adipose tissue resident macrophages produce more proinflammatory cytokines, such as tumor necrotic factor-α and interleukin-6, and less adiponectin. 23, 24) Epicardial fat looks like visceral fat that surrounds the heart and coronary arteries. Endocrine and paracrine activities, which lead to the secretion of pro-inflammatory and anti-inflammatory cytokines and chemokines, influence the development of coronary atherosclerosis. [25] [26] [27] Thus, epicardial fat is more important than paracardial fat for the progression of coronary atherosclerosis. Unexpectedly, paracardial fat was associated with Ueda, ET AL the presence of CAD in this study. We do not know why there was a discrepancy between these results. Only one report showed an association between paracardial fat and coronary artery calcification in postmenopausal women, and this association was dependent on estradiol levels. The authors reported that were associations between lower levels and greater declines of estradiol and paracardial fat, but not epicardial fat. 21) Although it is not clear why estradiol levels modulated coronary artery calcification, paracardial fat may be a potential menopause marker for the risk of CAD. Further studies will be needed to clarify this issue.
Visceral fat has been reported to be associated with atherosclerosis. 22) In this study, while visceral fat levels in the CAD group were significantly higher than those in the non-CAD group (Figure 2 ), the presence of CAD was not independently associated with visceral fat index (Supplemental Table III ). Since visceral fat index in the DM group (79 cm 2 /m 2 ) was significantly higher than that in the non-DM group (67 cm 2 /m 2 ) (P = 0.005), the presence of CAD may not be associated with visceral fat index independent of DM.
Age and DM in addition to the paracardial fat level were independent predictors for the presence of CAD. Age and DM are well-known essential risk factors for CAD. This result indicated that the subjects in this study were not a specific patient group. The CAD group was significantly older and showed higher levels of %male, prevalence of HTN, DM, DL, use of ARB/ACE-I, CCB, statin, β-blocker, SU, αGI and DPP-4I, visceral fat, MetS, hsCRP, pericardial fat, paracardial fat, and epicardial fat, and a significantly lower percentage of females and a lower level of HDL-C than the non-CAD group. It is reasonable that the CAD group had higher % medications for treatment than the non-CAD group because age, gender, HTN, DM, DL, and MetS are well-known essential risk factors for CAD. [28] [29] [30] [31] Study limitations: This study has several important limitations. First, the sample size was relatively small, which limited our ability to determine significance. Second, MDCT is not a gold standard for the evaluation of CAD, although recent studies have shown that both its sensitivity and specificity were approximately 95% of those for invasive coronary angiography for the identification of significant coronary stenosis. 26, 32) Third, although it was not very difficult to distinguish between paracardial and epicardial fat using 64-MDCT, we should obtain all fat data using the same MDCT. In addition, the need for an expert and the need for time to measure pericardial fat are drawbacks, and the development of analytical software is expected. A large-scale prospective study will be needed to address these issues.
Conclusions
Our results suggest that paracardial fat may be a marker for evaluating the presence or severity of CAD.
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